--- title: "AstraZeneca (AZN) Moves Deeper into Weight Loss Market with New $18.5B CSPC Agreement" type: "News" locale: "en" url: "https://longbridge.com/en/news/274293205.md" description: "AstraZeneca (AZN) has entered the obesity drug market with an $18.5 billion collaboration and licensing deal with CSPC Pharmaceuticals. This agreement allows AZN to develop and sell CSPC's long-acting peptide medicines and utilize its LiquidGel platform for monthly injections outside Greater China and Taiwan. The deal includes a $1.2 billion upfront payment and potential additional payments of up to $17.3 billion based on milestones. AstraZeneca aims to diversify its portfolio and compete in a market projected to exceed $100 billion, with a current Strong Buy rating from Wall Street." datetime: "2026-01-30T10:36:46.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/274293205.md) - [en](https://longbridge.com/en/news/274293205.md) - [zh-HK](https://longbridge.com/zh-HK/news/274293205.md) --- # AstraZeneca (AZN) Moves Deeper into Weight Loss Market with New $18.5B CSPC Agreement AstraZeneca (AZN) is making a major push into the fast-growing obesity drug market. The U.K. pharmaceutical giant has signed a collaboration and licensing deal with China's CSPC Pharmaceuticals, potentially valued at up to $18.5 billion. This deal grants AZN rights to develop and sell CSPC's long-acting peptide medicines and access to its LiquidGel platform for once-monthly injectable dosing outside Greater China and Taiwan. ### Claim 50% Off TipRanks Premium - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential The move comes as the company looks to diversify its portfolio beyond cancer and respiratory drugs. Also, it sees obesity treatments as one of the major new opportunities in healthcare. Also, the alliance was announced alongside a broader $15 billion investment plan by AstraZeneca to advance manufacturing and R&D within China. ## **Here's What the Agreement Includes** According to the terms of the deal, AstraZeneca will make a $1.2 billion upfront payment. Also, CSPC is eligible to receive up to $17.3 billion in additional payments if certain development, regulatory, and sales milestones are met. Further, CSPC will receive tiered, double-digit royalties on net sales outside of China. In return, the partnership gives AZN global rights to Eccogene's experimental oral GLP‑1 therapy. Importantly, the collaboration includes eight programs and provides access to CSPC's proprietary LiquidGel platform, which enables once-monthly injectable dosing, an approach that could boost patient adherence compared to daily or weekly injections. With the obesity drug market expected to surpass $100 billion in the next decade, AstraZeneca is positioning itself to compete with leaders such as Novo Nordisk (NVO) and Eli Lilly (LLY). ## **Is AZN a Good Stock to Buy Now?** Currently, Wall Street has a Strong Buy consensus rating on AstraZeneca stock based on four Buy recommendations. The average AZN stock price target of $106.75 implies an upside potential of 15.29%. ### Related Stocks - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [AZN.US](https://longbridge.com/en/quote/AZN.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) ## Related News & Research - [AstraZeneca Gets U.S. Approval for Hypertension Drug](https://longbridge.com/en/news/286724028.md) - [](https://longbridge.com/en/news/286601439.md) - [](https://longbridge.com/en/news/286807703.md) - [AstraZeneca's Imfinzi with pre-surgery drug boosts survival in bladder cancer trial](https://longbridge.com/en/news/286372424.md) - [AstraZeneca Tracks Real-World Sinus Surgery Outcomes in China: What Investors Should Watch](https://longbridge.com/en/news/286132902.md)